Skip to Content
Merck
  • Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).

Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).

Bioorganic & medicinal chemistry (2011-10-01)
Iris Thondorf, Valerie Voigt, Sarah Schäfer, Sabine Gebauer, Katja Zebisch, Linda Laug, Matthias Brandsch
ABSTRACT

The proton-coupled amino acid transporter hPAT1 has recently gained much interest due to its ability to transport small drugs thereby allowing their oral administration. A three-dimensional quantitative structure-activity relationship (3D QSAR) study has been performed on its natural and synthetic substrates employing comparative molecular similarity indices analysis (CoMSIA) to investigate the structural requirements for substrates and to derive a predictive model that may be used for the design of new prodrugs. The cross-validated CoMSIA models have been derived from a training set of 40 compounds and the predictive ability of the resulting models has been evaluated against a test set of 10 compounds. Despite the relatively narrow range of binding affinities (K(i) values) reliable statistical models with good predictive power have been obtained. The best CoMSIA model in terms of a proper balance of all statistical terms and the overall contribution of individual properties has been obtained by considering steric, hydrophobic, hydrogen bond donor and acceptor descriptors (q(cv)(2)=0.683, r(2)=0.958 and r(PRED)(2)=0.666). The 3D QSAR model provides insight in the interactions between substrates and hPAT1 on the molecular level and allows the prediction of affinity constants of new compounds. A pharmacophore model has been generated from the training set by means of the MOE (molecular operating environment) program. This model has been used as a query for virtual screening to retrieve potential new substrates from the small-molecule, 'lead-like' databases of MOE. The affinities of the compounds were predicted and 11 compounds were identified as possible high-affinity substrates. Two selected compounds strongly inhibited the hPAT mediated l-[(3)H]proline uptake into Caco-2 cells constitutively expressing the transport protein.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
D-Alanine, ≥98% (HPLC)
Sigma-Aldrich
cis-4-Hydroxy-L-proline, collagen synthesis inhibitor
Sigma-Aldrich
D-Cycloserine
Sigma-Aldrich
3-Guanidinopropionic acid
Sigma-Aldrich
L-Isoleucine, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
D-Cycloserine, synthetic
Sigma-Aldrich
α-(Methylamino)isobutyric acid, ≥97% (titration)
Sigma-Aldrich
L-Norvaline, arginase inhibitor
Sigma-Aldrich
D-Valine, BioReagent, suitable for cell culture
Sigma-Aldrich
Creatine, anhydrous
Sigma-Aldrich
L-Serine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Taurine, ≥99%
Sigma-Aldrich
Taurine, suitable for cell culture, meets USP testing specifications
Sigma-Aldrich
L-2-Aminobutyric acid, BioReagent, suitable for cell culture
Sigma-Aldrich
L-2-Aminobutyric acid, ≥99% (titration)
Sigma-Aldrich
L-Isoleucine, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
Piperidine solution, suitable for peptide synthesis, 20% in DMF
Sigma-Aldrich
Guanidineacetic acid, 99%
Sigma-Aldrich
L-Cysteine, ≥97%, FG
Sigma-Aldrich
Taurine, BioUltra, ≥99.5% (T)
SAFC
L-Cysteine
Sigma-Aldrich
L-Cysteine, 97%
Sigma-Aldrich
N-Methyl-L-alanine, ≥98.0% (TLC)
Sigma-Aldrich
L-Cysteine, BioUltra, ≥98.5% (RT)
Sigma-Aldrich
L-Serine, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
L-4-Thiazolidinecarboxylic acid, 98%
Sigma-Aldrich
Isonipecotic acid, 97%
Sigma-Aldrich
(S)-(+)-2-Pyrrolidinemethanol, 97%
Sigma-Aldrich
L-Cycloserine
Sigma-Aldrich
cis-4-Hydroxy-D-proline